Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02162147
Other study ID # 14/70X
Secondary ID 312463
Status Completed
Phase N/A
First received June 10, 2014
Last updated January 12, 2018
Start date November 2014
Est. completion date March 2017

Study information

Verified date January 2018
Source Children's Hospital of Eastern Ontario
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patient safety is an internationally recognized health care priority. Canadian data suggests that about 8% of adults admitted to hospital experience unintended harm (or 'adverse events') from the health care provided during their hospital stay. On a national level, this represents almost 25,000 preventable deaths among hospitalized adults each year. The emergency department is recognized as a high-risk environment for adverse events but most patient safety research is not specific to the emergency department. As well, the vast majority of people treated in the emergency department are sent home after their visit; yet safety research focuses primarily on people who are admitted to hospital. Finally, although children have also been identified as particularly high risk for suffering adverse events, very little research has been done on how often these events occur among children who visit the emergency department. Our study will address this gap in our knowledge about patient safety and provide important information on the frequency, severity and preventability of adverse events occurring among children in the emergency department. This information will help us to improve the safety of emergency department care for all Canadian children.


Recruitment information / eligibility

Status Completed
Enrollment 6385
Est. completion date March 2017
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria:

- Age less than 18 years

- Patients from all pediatric Canadian Triage Acuity Scale categories (pedsCTAS; 1:resuscitation; 2:emergent, 3:urgent, 4:semi-urgent, 5:non-urgent).

Exclusion Criteria:

- Insurmountable language barrier that prevents informed consent and follow-up by telephone.

- Children and families that will be unavailable for telephone follow-up in the three weeks after their emergency department visit (e.g., no telephone in the home, travelling out of the country, etc.).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada Alberta Children's Hospital Calgary Alberta
Canada Stollery Children's Hospital Edmonton Alberta
Canada Children's Hospital at London Health Sciences Centre London Ontario
Canada CHU Sainte-Justine Montreal Quebec
Canada Children's Hospital for Eastern Ontario Ottawa Ontario
Canada Janeway Children's Health and Rehabilitation Centre St. John Newfoundland and Labrador
Canada The Hospital for Sick Children Toronto Ontario
Canada BC Children's Hospital Vancouver British Columbia
Canada Manitoba Institute of Child Health Winnipeg Manitoba
Canada Winnipeg Children's Hospital Winnipeg Manitoba

Sponsors (11)

Lead Sponsor Collaborator
Children's Hospital of Eastern Ontario Alberta Children's Hospital, Janeway Children's Health and Rehabilitation Centre, London Health Sciences Centre, Manitoba Institute of Child Health, Ottawa Hospital Research Institute, Provincial Health Services Authority, St. Justine's Hospital, Stollery Children's Hospital, The Children's Hospital of Winnipeg, The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who experience an adverse event related to emergency department care within 3 weeks of an emergency department visit An adverse event will be defined as an event that results in unintended harm to the patient, and is related to the health care and/or services provided to the patient rather than to the patient's underlying medical condition. Emergency department care will be defined as any care provided in the emergency department and will explicitly include care provided by emergency department specific staff (i.e., staff physicians, nurses, and allied health care providers) and care provided by consultants in the emergency department. 3 weeks
Secondary Proportion of patients experiencing a preventable adverse event 3 weeks
Secondary Clinical severity of adverse events For all patients, we will report the clinical severity as: (a) an abnormality on laboratory testing, (b) =1 day of symptoms, (c) >1 day of symptoms, (d) nonpermanent disability (e) permanent disability, or (f) death. For admitted patients, we will also report clinical severity according to The Institute for Health Care Improvement trigger tool categories: (a) temporary harm to the patient requiring intervention, (b) temporary harm to the patient requiring initial or prolonged hospitalization, (c) permanent patient harm, (d) intervention required to sustain life, or (e) death. 3 weeks
Secondary Types of adverse events Adverse Events will be classified as (a) diagnostic issue, (b) management issue, (c) unsafe disposition decision, (d) suboptimal follow-up, (e) medication adverse effect, (f) procedural complication, and (g) nosocomial infection 3 weeks
Secondary System response required for adverse events The response will be classified as: (a) no treatment (symptoms only), (b) required medical/surgical intervention, (c) visit to MD office, (d) Emergency Department visit, (e) admission to hospital. These previously published broad categories were chosen in order to address the effect of the Adverse Events at both the patient and health care system level.These categories are not exclusive. 3 weeks
Secondary Proportion of patients for whom an adverse event is related to emergency department specific care Versus consulting specialty service care provided in the emergency department or care provided after the child's emergency department visit 3 weeks
Secondary Adverse events related to care provided in the emergency department by consulting service 3 weeks
Secondary Patient and system level characteristics associated with adverse events and preventable adverse events 3 weeks
Secondary Adverse events that occur within the 3-week time frame but are not related to care received in the emergency department Including those related to in-hospital care and primary care 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT03112083 - Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Recruiting NCT05799053 - Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study Phase 3